- Combination canagliflozin plus liraglutide therapy does not exert an additive action on glucose control in patients with type 2 diabetes (T2D), but does increase weight loss.
Why this matters
- The 2 are often prescribed together.
- 45 patients with T2D and HbA1c 7%-11% received 9-hour measurement of endogenous glucose production (EGP) and were randomly assigned to liraglutide 1.2 mg/day, canagliflozin 100 mg/day, or liraglutide 1.2 mg plus canagliflozin 100 mg for 16 weeks; then EGP measurement was repeated.
- Funding: Janssen Pharmaceuticals.
- Mean HbA1c decreases from baseline to 16 weeks:
- Combination: −1.67 (P=.0001).
- Canagliflozin: −0.89 (P=.002).
- Liraglutide: −1.44 (P=.004).
- No significant differences among treatments.
- Mean body weight decreases from baseline:
- Combination: −6.0 kg (P<.0001>
- Canagliflozin: −3.5 kg (P<.0001>
- Liraglutide: −1.9 kg (P=.03).
- Steeper with the combination vs canagliflozin (P=.01) or liraglutide (P=.002).
- No placebo group.
- Food intake, physical activity not measured.